As of July 24, 2025, Daré Bioscience, Inc. has demonstrated compliance with Nasdaq's stockholders' equity requirement, thus meeting the continued listing requirements of the Nasdaq Capital Market. However, the company will be monitored for one year by a Mandatory Panel Monitor to ensure ongoing compliance. If Daré Bioscience falls out of compliance within this period, they will receive a delist determination letter and may request a new hearing with Nasdaq's Hearings Panel.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-011402), on July 25, 2025, and is solely responsible for the information contained therein.